BioInvent International (STO:BINV)46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate (12 of 13) in relapsed/refractory CTCLImmune activation confirmed by CD8+ T ...
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have access to controlled substances for legitimate medical use.Today, the evidence shows the opposite: ...
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit ...
VANCOUVER, BC / ACCESS Newswire / December 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has ...
VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)Multidose data demonstrate substantial reductions ...
New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial ...
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation (OTC:HIRU) ("Ameerex" or the "Company"), a natural-resources group owned and managed by high-profile Qatari ...
Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in ...
Data presented was selected for ASH’s exclusive program to highlight the most impactful research submitted for this year’s meetingReal-world data reinforces the value of durable, one-time gene ...
Key HighlightsMotixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies90% (9 of 10) of patients ...
Powering the Cost Plus Marketplace for Businesses Through Transparency, Innovation and Trust Mark Cuban and David Zilberman ...
In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback